NuCana (NASDAQ:NCNA) Releases Quarterly Earnings Results, Beats Expectations By $1.39 EPS

NuCana (NASDAQ:NCNA) posted its earnings results on Thursday. The company reported ($1.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.64) by $1.39, Zacks reports.

NuCana Stock Up 10.1%

Shares of NuCana stock opened at $2.18 on Friday. The stock has a market capitalization of $9.07 million, a P/E ratio of -0.73 and a beta of 2.17. The company has a 50-day simple moving average of $1.93 and a 200 day simple moving average of $2.79. NuCana has a 12-month low of $1.33 and a 12-month high of $40.00.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of NuCana in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has an average rating of “Sell”.

About NuCana

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.